COVID-19 Impact on Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size, Status and Forecast 2020-2026
This report focuses on the global Targeted Drug EGFR RTK Inhibitors for NSCLC status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Targeted Drug EGFR RTK Inhibitors for NSCLC development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study
The key players covered in this study
- Beta Pharma
- AstraZeneca
- Natco Pharma
- Qilu Pharmaceutical
- Genentech (Roche Group)
- Mylan
- Teva
- OSI Pharmaceuticals
- Glenmark Pharmaceuticals
- Beacon Pharmaceuticals
- Boehringer Ingelheim
- Pfizer
- ARIAD Pharmaceuticals (Takeda)
- Genvio Pharma Limited
- Drug International Limted
- Everest Pharmaceuticals
- Incepta Pharmaceuticals Limited
- Cipla Pharma
- Dr Reddy's Laboratories
- Zydus Cadila
- Hetero Drugs
- Intas Pharmaceuticals
- Alkem Laboratories
- RPG Life Sciences
- Fresenius Kabi India
- Icotinib
- Gefitinib
- Erlotinib
- Afatinib
- Osimertinib
- Brigatinib
- Other
- Squamous Cell Carcinoma of NSCLC
- Adenocarcinoma of NSCLC
- Large Cell Carcinoma of NSCLC
- North America
- Europe
- China
- Japan
- Southeast Asia
- India
- Central & South America
- To analyze global Targeted Drug EGFR RTK Inhibitors for NSCLC status, future forecast, growth opportunity, key market and key players.
- To present the Targeted Drug EGFR RTK Inhibitors for NSCLC development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
- To strategically profile the key players and comprehensively analyze their development plan and strategies.
- To define, describe and forecast the market by type, market and key regions.
- History Year: 2015-2019
- Base Year: 2019
- Estimated Year: 2020
- Forecast Year 2020 to 2026
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue
1.4 Market Analysis by Type
1.4.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Icotinib
1.4.3 Gefitinib
1.4.4 Erlotinib
1.4.5 Afatinib
1.4.6 Osimertinib
1.4.7 Brigatinib
1.4.8 Other
1.5 Market by Application
1.5.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application: 2020 VS 2026
1.5.2 Squamous Cell Carcinoma of NSCLC
1.5.3 Adenocarcinoma of NSCLC
1.5.4 Large Cell Carcinoma of NSCLC
1.6 Coronavirus Disease 2019 (Covid-19): Targeted Drug EGFR RTK Inhibitors for NSCLC Industry Impact
1.6.1 How the Covid-19 is Affecting the Targeted Drug EGFR RTK Inhibitors for NSCLC Industry
1.6.1.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Targeted Drug EGFR RTK Inhibitors for NSCLC Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Targeted Drug EGFR RTK Inhibitors for NSCLC Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 GLOBAL GROWTH TRENDS BY REGIONS
2.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Perspective (2015-2026)
2.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Growth Trends by Regions
2.2.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Historic Market Share by Regions (2015-2020)
2.2.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Growth Strategy
2.3.6 Primary Interviews with Key Targeted Drug EGFR RTK Inhibitors for NSCLC Players (Opinion Leaders)
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Targeted Drug EGFR RTK Inhibitors for NSCLC Players by Market Size
3.1.1 Global Top Targeted Drug EGFR RTK Inhibitors for NSCLC Players by Revenue (2015-2020)
3.1.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Players (2015-2020)
3.1.3 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Concentration Ratio
3.2.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue in 2019
3.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players Head office and Area Served
3.4 Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Product Solution and Service
3.5 Date of Enter into Targeted Drug EGFR RTK Inhibitors for NSCLC Market
3.6 Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Historic Market Size by Type (2015-2020)
4.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecasted Market Size by Type (2021-2026)
5 TARGETED DRUG EGFR RTK INHIBITORS FOR NSCLC BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020)
5.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecasted Market Size by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2015-2020)
6.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in North America (2019-2020)
6.3 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020)
6.4 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020)
7 EUROPE
7.1 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2015-2020)
7.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in Europe (2019-2020)
7.3 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020)
7.4 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020)
8 CHINA
8.1 China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2015-2020)
8.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in China (2019-2020)
8.3 China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020)
8.4 China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020)
9 JAPAN
9.1 Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2015-2020)
9.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in Japan (2019-2020)
9.3 Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020)
9.4 Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020)
10 SOUTHEAST ASIA
10.1 Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2015-2020)
10.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020)
10.4 Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020)
11 INDIA
11.1 India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2015-2020)
11.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in India (2019-2020)
11.3 India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020)
11.4 India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020)
12 CENTRAL & SOUTH AMERICA
12.1 Central & South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2015-2020)
12.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in Central & South America (2019-2020)
12.3 Central & South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020)
12.4 Central & South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020)
13 KEY PLAYERS PROFILES
13.1 Beta Pharma
13.1.1 Beta Pharma Company Details
13.1.2 Beta Pharma Business Overview and Its Total Revenue
13.1.3 Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
13.1.4 Beta Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020))
13.1.5 Beta Pharma Recent Development
13.2 AstraZeneca
13.2.1 AstraZeneca Company Details
13.2.2 AstraZeneca Business Overview and Its Total Revenue
13.2.3 AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
13.2.4 AstraZeneca Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
13.2.5 AstraZeneca Recent Development
13.3 Natco Pharma
13.3.1 Natco Pharma Company Details
13.3.2 Natco Pharma Business Overview and Its Total Revenue
13.3.3 Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
13.3.4 Natco Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
13.3.5 Natco Pharma Recent Development
13.4 Qilu Pharmaceutical
13.4.1 Qilu Pharmaceutical Company Details
13.4.2 Qilu Pharmaceutical Business Overview and Its Total Revenue
13.4.3 Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
13.4.4 Qilu Pharmaceutical Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
13.4.5 Qilu Pharmaceutical Recent Development
13.5 Genentech (Roche Group)
13.5.1 Genentech (Roche Group) Company Details
13.5.2 Genentech (Roche Group) Business Overview and Its Total Revenue
13.5.3 Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
13.5.4 Genentech (Roche Group) Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
13.5.5 Genentech (Roche Group) Recent Development
13.6 Mylan
13.6.1 Mylan Company Details
13.6.2 Mylan Business Overview and Its Total Revenue
13.6.3 Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
13.6.4 Mylan Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
13.6.5 Mylan Recent Development
13.7 Teva
13.7.1 Teva Company Details
13.7.2 Teva Business Overview and Its Total Revenue
13.7.3 Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
13.7.4 Teva Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
13.7.5 Teva Recent Development
13.8 OSI Pharmaceuticals
13.8.1 OSI Pharmaceuticals Company Details
13.8.2 OSI Pharmaceuticals Business Overview and Its Total Revenue
13.8.3 OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
13.8.4 OSI Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
13.8.5 OSI Pharmaceuticals Recent Development
13.9 Glenmark Pharmaceuticals
13.9.1 Glenmark Pharmaceuticals Company Details
13.9.2 Glenmark Pharmaceuticals Business Overview and Its Total Revenue
13.9.3 Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
13.9.4 Glenmark Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
13.9.5 Glenmark Pharmaceuticals Recent Development
13.10 Beacon Pharmaceuticals
13.10.1 Beacon Pharmaceuticals Company Details
13.10.2 Beacon Pharmaceuticals Business Overview and Its Total Revenue
13.10.3 Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
13.10.4 Beacon Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
13.10.5 Beacon Pharmaceuticals Recent Development
13.11 Boehringer Ingelheim
10.11.1 Boehringer Ingelheim Company Details
10.11.2 Boehringer Ingelheim Business Overview and Its Total Revenue
10.11.3 Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
10.11.4 Boehringer Ingelheim Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
10.11.5 Boehringer Ingelheim Recent Development
13.12 Pfizer
10.12.1 Pfizer Company Details
10.12.2 Pfizer Business Overview and Its Total Revenue
10.12.3 Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
10.12.4 Pfizer Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
10.12.5 Pfizer Recent Development
13.13 ARIAD Pharmaceuticals (Takeda)
10.13.1 ARIAD Pharmaceuticals (Takeda) Company Details
10.13.2 ARIAD Pharmaceuticals (Takeda) Business Overview and Its Total Revenue
10.13.3 ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
10.13.4 ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
10.13.5 ARIAD Pharmaceuticals (Takeda) Recent Development
13.14 Genvio Pharma Limited
10.14.1 Genvio Pharma Limited Company Details
10.14.2 Genvio Pharma Limited Business Overview and Its Total Revenue
10.14.3 Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
10.14.4 Genvio Pharma Limited Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
10.14.5 Genvio Pharma Limited Recent Development
13.15 Drug International Limted
10.15.1 Drug International Limted Company Details
10.15.2 Drug International Limted Business Overview and Its Total Revenue
10.15.3 Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
10.15.4 Drug International Limted Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
10.15.5 Drug International Limted Recent Development
13.16 Everest Pharmaceuticals
10.16.1 Everest Pharmaceuticals Company Details
10.16.2 Everest Pharmaceuticals Business Overview and Its Total Revenue
10.16.3 Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
10.16.4 Everest Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
10.16.5 Everest Pharmaceuticals Recent Development
13.17 Incepta Pharmaceuticals Limited
10.17.1 Incepta Pharmaceuticals Limited Company Details
10.17.2 Incepta Pharmaceuticals Limited Business Overview and Its Total Revenue
10.17.3 Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
10.17.4 Incepta Pharmaceuticals Limited Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
10.17.5 Incepta Pharmaceuticals Limited Recent Development
13.18 Cipla Pharma
10.18.1 Cipla Pharma Company Details
10.18.2 Cipla Pharma Business Overview and Its Total Revenue
10.18.3 Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
10.18.4 Cipla Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
10.18.5 Cipla Pharma Recent Development
13.19 Dr Reddy's Laboratories
10.19.1 Dr Reddy's Laboratories Company Details
10.19.2 Dr Reddy's Laboratories Business Overview and Its Total Revenue
10.19.3 Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
10.19.4 Dr Reddy's Laboratories Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
10.19.5 Dr Reddy's Laboratories Recent Development
13.20 Zydus Cadila
10.20.1 Zydus Cadila Company Details
10.20.2 Zydus Cadila Business Overview and Its Total Revenue
10.20.3 Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
10.20.4 Zydus Cadila Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
10.20.5 Zydus Cadila Recent Development
13.21 Hetero Drugs
10.21.1 Hetero Drugs Company Details
10.21.2 Hetero Drugs Business Overview and Its Total Revenue
10.21.3 Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
10.21.4 Hetero Drugs Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
10.21.5 Hetero Drugs Recent Development
13.22 Intas Pharmaceuticals
10.22.1 Intas Pharmaceuticals Company Details
10.22.2 Intas Pharmaceuticals Business Overview and Its Total Revenue
10.22.3 Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
10.22.4 Intas Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
10.22.5 Intas Pharmaceuticals Recent Development
13.23 Alkem Laboratories
10.23.1 Alkem Laboratories Company Details
10.23.2 Alkem Laboratories Business Overview and Its Total Revenue
10.23.3 Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
10.23.4 Alkem Laboratories Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
10.23.5 Alkem Laboratories Recent Development
13.24 RPG Life Sciences
10.24.1 RPG Life Sciences Company Details
10.24.2 RPG Life Sciences Business Overview and Its Total Revenue
10.24.3 RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
10.24.4 RPG Life Sciences Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
10.24.5 RPG Life Sciences Recent Development
13.25 Fresenius Kabi India
10.25.1 Fresenius Kabi India Company Details
10.25.2 Fresenius Kabi India Business Overview and Its Total Revenue
10.25.3 Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
10.25.4 Fresenius Kabi India Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
10.25.5 Fresenius Kabi India Recent Development
14 ANALYST'S VIEWPOINTS/CONCLUSIONS
15 APPENDIX
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue
1.4 Market Analysis by Type
1.4.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Icotinib
1.4.3 Gefitinib
1.4.4 Erlotinib
1.4.5 Afatinib
1.4.6 Osimertinib
1.4.7 Brigatinib
1.4.8 Other
1.5 Market by Application
1.5.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application: 2020 VS 2026
1.5.2 Squamous Cell Carcinoma of NSCLC
1.5.3 Adenocarcinoma of NSCLC
1.5.4 Large Cell Carcinoma of NSCLC
1.6 Coronavirus Disease 2019 (Covid-19): Targeted Drug EGFR RTK Inhibitors for NSCLC Industry Impact
1.6.1 How the Covid-19 is Affecting the Targeted Drug EGFR RTK Inhibitors for NSCLC Industry
1.6.1.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Targeted Drug EGFR RTK Inhibitors for NSCLC Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Targeted Drug EGFR RTK Inhibitors for NSCLC Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 GLOBAL GROWTH TRENDS BY REGIONS
2.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Perspective (2015-2026)
2.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Growth Trends by Regions
2.2.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Historic Market Share by Regions (2015-2020)
2.2.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Growth Strategy
2.3.6 Primary Interviews with Key Targeted Drug EGFR RTK Inhibitors for NSCLC Players (Opinion Leaders)
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Targeted Drug EGFR RTK Inhibitors for NSCLC Players by Market Size
3.1.1 Global Top Targeted Drug EGFR RTK Inhibitors for NSCLC Players by Revenue (2015-2020)
3.1.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Players (2015-2020)
3.1.3 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Concentration Ratio
3.2.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue in 2019
3.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players Head office and Area Served
3.4 Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Product Solution and Service
3.5 Date of Enter into Targeted Drug EGFR RTK Inhibitors for NSCLC Market
3.6 Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Historic Market Size by Type (2015-2020)
4.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecasted Market Size by Type (2021-2026)
5 TARGETED DRUG EGFR RTK INHIBITORS FOR NSCLC BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020)
5.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecasted Market Size by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2015-2020)
6.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in North America (2019-2020)
6.3 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020)
6.4 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020)
7 EUROPE
7.1 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2015-2020)
7.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in Europe (2019-2020)
7.3 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020)
7.4 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020)
8 CHINA
8.1 China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2015-2020)
8.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in China (2019-2020)
8.3 China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020)
8.4 China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020)
9 JAPAN
9.1 Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2015-2020)
9.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in Japan (2019-2020)
9.3 Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020)
9.4 Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020)
10 SOUTHEAST ASIA
10.1 Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2015-2020)
10.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020)
10.4 Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020)
11 INDIA
11.1 India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2015-2020)
11.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in India (2019-2020)
11.3 India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020)
11.4 India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020)
12 CENTRAL & SOUTH AMERICA
12.1 Central & South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2015-2020)
12.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in Central & South America (2019-2020)
12.3 Central & South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020)
12.4 Central & South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020)
13 KEY PLAYERS PROFILES
13.1 Beta Pharma
13.1.1 Beta Pharma Company Details
13.1.2 Beta Pharma Business Overview and Its Total Revenue
13.1.3 Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
13.1.4 Beta Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020))
13.1.5 Beta Pharma Recent Development
13.2 AstraZeneca
13.2.1 AstraZeneca Company Details
13.2.2 AstraZeneca Business Overview and Its Total Revenue
13.2.3 AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
13.2.4 AstraZeneca Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
13.2.5 AstraZeneca Recent Development
13.3 Natco Pharma
13.3.1 Natco Pharma Company Details
13.3.2 Natco Pharma Business Overview and Its Total Revenue
13.3.3 Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
13.3.4 Natco Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
13.3.5 Natco Pharma Recent Development
13.4 Qilu Pharmaceutical
13.4.1 Qilu Pharmaceutical Company Details
13.4.2 Qilu Pharmaceutical Business Overview and Its Total Revenue
13.4.3 Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
13.4.4 Qilu Pharmaceutical Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
13.4.5 Qilu Pharmaceutical Recent Development
13.5 Genentech (Roche Group)
13.5.1 Genentech (Roche Group) Company Details
13.5.2 Genentech (Roche Group) Business Overview and Its Total Revenue
13.5.3 Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
13.5.4 Genentech (Roche Group) Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
13.5.5 Genentech (Roche Group) Recent Development
13.6 Mylan
13.6.1 Mylan Company Details
13.6.2 Mylan Business Overview and Its Total Revenue
13.6.3 Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
13.6.4 Mylan Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
13.6.5 Mylan Recent Development
13.7 Teva
13.7.1 Teva Company Details
13.7.2 Teva Business Overview and Its Total Revenue
13.7.3 Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
13.7.4 Teva Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
13.7.5 Teva Recent Development
13.8 OSI Pharmaceuticals
13.8.1 OSI Pharmaceuticals Company Details
13.8.2 OSI Pharmaceuticals Business Overview and Its Total Revenue
13.8.3 OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
13.8.4 OSI Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
13.8.5 OSI Pharmaceuticals Recent Development
13.9 Glenmark Pharmaceuticals
13.9.1 Glenmark Pharmaceuticals Company Details
13.9.2 Glenmark Pharmaceuticals Business Overview and Its Total Revenue
13.9.3 Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
13.9.4 Glenmark Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
13.9.5 Glenmark Pharmaceuticals Recent Development
13.10 Beacon Pharmaceuticals
13.10.1 Beacon Pharmaceuticals Company Details
13.10.2 Beacon Pharmaceuticals Business Overview and Its Total Revenue
13.10.3 Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
13.10.4 Beacon Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
13.10.5 Beacon Pharmaceuticals Recent Development
13.11 Boehringer Ingelheim
10.11.1 Boehringer Ingelheim Company Details
10.11.2 Boehringer Ingelheim Business Overview and Its Total Revenue
10.11.3 Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
10.11.4 Boehringer Ingelheim Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
10.11.5 Boehringer Ingelheim Recent Development
13.12 Pfizer
10.12.1 Pfizer Company Details
10.12.2 Pfizer Business Overview and Its Total Revenue
10.12.3 Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
10.12.4 Pfizer Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
10.12.5 Pfizer Recent Development
13.13 ARIAD Pharmaceuticals (Takeda)
10.13.1 ARIAD Pharmaceuticals (Takeda) Company Details
10.13.2 ARIAD Pharmaceuticals (Takeda) Business Overview and Its Total Revenue
10.13.3 ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
10.13.4 ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
10.13.5 ARIAD Pharmaceuticals (Takeda) Recent Development
13.14 Genvio Pharma Limited
10.14.1 Genvio Pharma Limited Company Details
10.14.2 Genvio Pharma Limited Business Overview and Its Total Revenue
10.14.3 Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
10.14.4 Genvio Pharma Limited Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
10.14.5 Genvio Pharma Limited Recent Development
13.15 Drug International Limted
10.15.1 Drug International Limted Company Details
10.15.2 Drug International Limted Business Overview and Its Total Revenue
10.15.3 Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
10.15.4 Drug International Limted Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
10.15.5 Drug International Limted Recent Development
13.16 Everest Pharmaceuticals
10.16.1 Everest Pharmaceuticals Company Details
10.16.2 Everest Pharmaceuticals Business Overview and Its Total Revenue
10.16.3 Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
10.16.4 Everest Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
10.16.5 Everest Pharmaceuticals Recent Development
13.17 Incepta Pharmaceuticals Limited
10.17.1 Incepta Pharmaceuticals Limited Company Details
10.17.2 Incepta Pharmaceuticals Limited Business Overview and Its Total Revenue
10.17.3 Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
10.17.4 Incepta Pharmaceuticals Limited Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
10.17.5 Incepta Pharmaceuticals Limited Recent Development
13.18 Cipla Pharma
10.18.1 Cipla Pharma Company Details
10.18.2 Cipla Pharma Business Overview and Its Total Revenue
10.18.3 Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
10.18.4 Cipla Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
10.18.5 Cipla Pharma Recent Development
13.19 Dr Reddy's Laboratories
10.19.1 Dr Reddy's Laboratories Company Details
10.19.2 Dr Reddy's Laboratories Business Overview and Its Total Revenue
10.19.3 Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
10.19.4 Dr Reddy's Laboratories Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
10.19.5 Dr Reddy's Laboratories Recent Development
13.20 Zydus Cadila
10.20.1 Zydus Cadila Company Details
10.20.2 Zydus Cadila Business Overview and Its Total Revenue
10.20.3 Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
10.20.4 Zydus Cadila Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
10.20.5 Zydus Cadila Recent Development
13.21 Hetero Drugs
10.21.1 Hetero Drugs Company Details
10.21.2 Hetero Drugs Business Overview and Its Total Revenue
10.21.3 Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
10.21.4 Hetero Drugs Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
10.21.5 Hetero Drugs Recent Development
13.22 Intas Pharmaceuticals
10.22.1 Intas Pharmaceuticals Company Details
10.22.2 Intas Pharmaceuticals Business Overview and Its Total Revenue
10.22.3 Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
10.22.4 Intas Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
10.22.5 Intas Pharmaceuticals Recent Development
13.23 Alkem Laboratories
10.23.1 Alkem Laboratories Company Details
10.23.2 Alkem Laboratories Business Overview and Its Total Revenue
10.23.3 Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
10.23.4 Alkem Laboratories Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
10.23.5 Alkem Laboratories Recent Development
13.24 RPG Life Sciences
10.24.1 RPG Life Sciences Company Details
10.24.2 RPG Life Sciences Business Overview and Its Total Revenue
10.24.3 RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
10.24.4 RPG Life Sciences Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
10.24.5 RPG Life Sciences Recent Development
13.25 Fresenius Kabi India
10.25.1 Fresenius Kabi India Company Details
10.25.2 Fresenius Kabi India Business Overview and Its Total Revenue
10.25.3 Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
10.25.4 Fresenius Kabi India Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
10.25.5 Fresenius Kabi India Recent Development
14 ANALYST'S VIEWPOINTS/CONCLUSIONS
15 APPENDIX
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
LIST OF TABLES
Table 1. Targeted Drug EGFR RTK Inhibitors for NSCLC Key Market Segments
Table 2. Key Players Covered: Ranking by Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue
Table 3. Ranking of Global Top Targeted Drug EGFR RTK Inhibitors for NSCLC Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Icotinib
Table 6. Key Players of Gefitinib
Table 7. Key Players of Erlotinib
Table 8. Key Players of Afatinib
Table 9. Key Players of Osimertinib
Table 10. Key Players of Brigatinib
Table 11. Key Players of Other
Table 12. COVID-19 Impact Global Market: (Four Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast Scenarios)
Table 13. Opportunities and Trends for Targeted Drug EGFR RTK Inhibitors for NSCLC Players in the COVID-19 Landscape
Table 14. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 15. Key Regions/Countries Measures against Covid-19 Impact
Table 16. Proposal for Targeted Drug EGFR RTK Inhibitors for NSCLC Players to Combat Covid-19 Impact
Table 17. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 18. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Regions (US$ Million): 2020 VS 2026
Table 19. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Regions (2015-2020) (US$ Million)
Table 20. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Regions (2015-2020)
Table 21. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 22. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Regions (2021-2026)
Table 23. Market Top Trends
Table 24. Key Drivers: Impact Analysis
Table 25. Key Challenges
Table 26. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Growth Strategy
Table 27. Main Points Interviewed from Key Targeted Drug EGFR RTK Inhibitors for NSCLC Players
Table 28. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Players (2015-2020) (Million US$)
Table 29. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Players (2015-2020)
Table 30. Global Top Targeted Drug EGFR RTK Inhibitors for NSCLC Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC as of 2019)
Table 31. Global Targeted Drug EGFR RTK Inhibitors for NSCLC by Players Market Concentration Ratio (CR5 and HHI)
Table 32. Key Players Headquarters and Area Served
Table 33. Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Product Solution and Service
Table 34. Date of Enter into Targeted Drug EGFR RTK Inhibitors for NSCLC Market
Table 35. Mergers & Acquisitions, Expansion Plans
Table 36. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 37. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Share by Type (2015-2020)
Table 38. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Type (2021-2026)
Table 39. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Share by Application (2015-2020)
Table 40. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 41. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Share by Application (2021-2026)
Table 42. North America Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (2019-2020) (Million US$)
Table 43. North America Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share (2019-2020)
Table 44. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 45. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2015-2020)
Table 46. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 47. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2015-2020)
Table 48. Europe Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (2019-2020) (Million US$)
Table 49. Europe Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share (2019-2020)
Table 50. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 51. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2015-2020)
Table 52. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 53. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2015-2020)
Table 54. China Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (2019-2020) (Million US$)
Table 55. China Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share (2019-2020)
Table 56. China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 57. China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2015-2020)
Table 58. China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 59. China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2015-2020)
Table 60. Japan Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (2019-2020) (Million US$)
Table 61. Japan Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share (2019-2020)
Table 62. Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 63. Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2015-2020)
Table 64. Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 65. Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2015-2020)
Table 66. Southeast Asia Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (2019-2020) (Million US$)
Table 67. Southeast Asia Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share (2019-2020)
Table 68. Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 69. Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2015-2020)
Table 70. Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 71. Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2015-2020)
Table 72. India Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (2019-2020) (Million US$)
Table 73. India Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share (2019-2020)
Table 74. India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 75. India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2015-2020)
Table 76. India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 77. India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2015-2020)
Table 78. Central & South America Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (2019-2020) (Million US$)
Table 79. Central & South America Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share (2019-2020)
Table 80. Central & South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 81. Central & South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2015-2020)
Table 82. Central & South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 83. Central & South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2015-2020)
Table 84. Beta Pharma Company Details
Table 85. Beta Pharma Business Overview
Table 86. Beta Pharma Product
Table 87. Beta Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 88. Beta Pharma Recent Development
Table 89. AstraZeneca Company Details
Table 90. AstraZeneca Business Overview
Table 91. AstraZeneca Product
Table 92. AstraZeneca Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 93. AstraZeneca Recent Development
Table 94. Natco Pharma Company Details
Table 95. Natco Pharma Business Overview
Table 96. Natco Pharma Product
Table 97. Natco Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 98. Natco Pharma Recent Development
Table 99. Qilu Pharmaceutical Company Details
Table 100. Qilu Pharmaceutical Business Overview
Table 101. Qilu Pharmaceutical Product
Table 102. Qilu Pharmaceutical Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 103. Qilu Pharmaceutical Recent Development
Table 104. Genentech (Roche Group) Company Details
Table 105. Genentech (Roche Group) Business Overview
Table 106. Genentech (Roche Group) Product
Table 107. Genentech (Roche Group) Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 108. Genentech (Roche Group) Recent Development
Table 109. Mylan Company Details
Table 110. Mylan Business Overview
Table 111. Mylan Product
Table 112. Mylan Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 113. Mylan Recent Development
Table 114. Teva Company Details
Table 115. Teva Business Overview
Table 116. Teva Product
Table 117. Teva Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 118. Teva Recent Development
Table 119. OSI Pharmaceuticals Business Overview
Table 120. OSI Pharmaceuticals Product
Table 121. OSI Pharmaceuticals Company Details
Table 122. OSI Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 123. OSI Pharmaceuticals Recent Development
Table 124. Glenmark Pharmaceuticals Company Details
Table 125. Glenmark Pharmaceuticals Business Overview
Table 126. Glenmark Pharmaceuticals Product
Table 127. Glenmark Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 128. Glenmark Pharmaceuticals Recent Development
Table 129. Beacon Pharmaceuticals Company Details
Table 130. Beacon Pharmaceuticals Business Overview
Table 131. Beacon Pharmaceuticals Product
Table 132. Beacon Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 133. Beacon Pharmaceuticals Recent Development
Table 134. Boehringer Ingelheim Company Details
Table 135. Boehringer Ingelheim Business Overview
Table 136. Boehringer Ingelheim Product
Table 137. Boehringer Ingelheim Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 138. Boehringer Ingelheim Recent Development
Table 139. Pfizer Company Details
Table 140. Pfizer Business Overview
Table 141. Pfizer Product
Table 142. Pfizer Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 143. Pfizer Recent Development
Table 144. ARIAD Pharmaceuticals (Takeda) Company Details
Table 145. ARIAD Pharmaceuticals (Takeda) Business Overview
Table 146. ARIAD Pharmaceuticals (Takeda) Product
Table 147. ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 148. ARIAD Pharmaceuticals (Takeda) Recent Development
Table 149. Genvio Pharma Limited Company Details
Table 150. Genvio Pharma Limited Business Overview
Table 151. Genvio Pharma Limited Product
Table 152. Genvio Pharma Limited Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 153. Genvio Pharma Limited Recent Development
Table 154. Drug International Limted Company Details
Table 155. Drug International Limted Business Overview
Table 156. Drug International Limted Product
Table 157. Drug International Limted Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 158. Drug International Limted Recent Development
Table 159. Everest Pharmaceuticals Company Details
Table 160. Everest Pharmaceuticals Business Overview
Table 161. Everest Pharmaceuticals Product
Table 162. Everest Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 163. Everest Pharmaceuticals Recent Development
Table 164. Incepta Pharmaceuticals Limited Company Details
Table 165. Incepta Pharmaceuticals Limited Business Overview
Table 166. Incepta Pharmaceuticals Limited Product
Table 167. Incepta Pharmaceuticals Limited Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 168. Incepta Pharmaceuticals Limited Recent Development
Table 169. Cipla Pharma Company Details
Table 170. Cipla Pharma Business Overview
Table 171. Cipla Pharma Product
Table 172. Cipla Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 173. Cipla Pharma Recent Development
Table 174. Dr Reddy's Laboratories Company Details
Table 175. Dr Reddy's Laboratories Business Overview
Table 176. Dr Reddy's Laboratories Product
Table 177. Dr Reddy's Laboratories Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 178. Dr Reddy's Laboratories Recent Development
Table 179. Zydus Cadila Company Details
Table 180. Zydus Cadila Business Overview
Table 181. Zydus Cadila Product
Table 182. Zydus Cadila Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 183. Zydus Cadila Recent Development
Table 184. Hetero Drugs Company Details
Table 185. Hetero Drugs Business Overview
Table 186. Hetero Drugs Product
Table 187. Hetero Drugs Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 188. Hetero Drugs Recent Development
Table 189. Intas Pharmaceuticals Company Details
Table 190. Intas Pharmaceuticals Business Overview
Table 191. Intas Pharmaceuticals Product
Table 192. Intas Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 193. Intas Pharmaceuticals Recent Development
Table 194. Alkem Laboratories Company Details
Table 195. Alkem Laboratories Business Overview
Table 196. Alkem Laboratories Product
Table 197. Alkem Laboratories Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 198. Alkem Laboratories Recent Development
Table 199. RPG Life Sciences Company Details
Table 200. RPG Life Sciences Business Overview
Table 201. RPG Life Sciences Product
Table 202. RPG Life Sciences Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 203. RPG Life Sciences Recent Development
Table 204. Fresenius Kabi India Company Details
Table 205. Fresenius Kabi India Business Overview
Table 206. Fresenius Kabi India Product
Table 207. Fresenius Kabi India Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 208. Fresenius Kabi India Recent Development
Table 209. Research Programs/Design for This Report
Table 210. Key Data Information from Secondary Sources
Table 211. Key Data Information from Primary Sources
Table 1. Targeted Drug EGFR RTK Inhibitors for NSCLC Key Market Segments
Table 2. Key Players Covered: Ranking by Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue
Table 3. Ranking of Global Top Targeted Drug EGFR RTK Inhibitors for NSCLC Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Icotinib
Table 6. Key Players of Gefitinib
Table 7. Key Players of Erlotinib
Table 8. Key Players of Afatinib
Table 9. Key Players of Osimertinib
Table 10. Key Players of Brigatinib
Table 11. Key Players of Other
Table 12. COVID-19 Impact Global Market: (Four Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast Scenarios)
Table 13. Opportunities and Trends for Targeted Drug EGFR RTK Inhibitors for NSCLC Players in the COVID-19 Landscape
Table 14. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 15. Key Regions/Countries Measures against Covid-19 Impact
Table 16. Proposal for Targeted Drug EGFR RTK Inhibitors for NSCLC Players to Combat Covid-19 Impact
Table 17. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 18. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Regions (US$ Million): 2020 VS 2026
Table 19. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Regions (2015-2020) (US$ Million)
Table 20. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Regions (2015-2020)
Table 21. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 22. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Regions (2021-2026)
Table 23. Market Top Trends
Table 24. Key Drivers: Impact Analysis
Table 25. Key Challenges
Table 26. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Growth Strategy
Table 27. Main Points Interviewed from Key Targeted Drug EGFR RTK Inhibitors for NSCLC Players
Table 28. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Players (2015-2020) (Million US$)
Table 29. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Players (2015-2020)
Table 30. Global Top Targeted Drug EGFR RTK Inhibitors for NSCLC Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC as of 2019)
Table 31. Global Targeted Drug EGFR RTK Inhibitors for NSCLC by Players Market Concentration Ratio (CR5 and HHI)
Table 32. Key Players Headquarters and Area Served
Table 33. Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Product Solution and Service
Table 34. Date of Enter into Targeted Drug EGFR RTK Inhibitors for NSCLC Market
Table 35. Mergers & Acquisitions, Expansion Plans
Table 36. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 37. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Share by Type (2015-2020)
Table 38. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Type (2021-2026)
Table 39. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Share by Application (2015-2020)
Table 40. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 41. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Share by Application (2021-2026)
Table 42. North America Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (2019-2020) (Million US$)
Table 43. North America Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share (2019-2020)
Table 44. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 45. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2015-2020)
Table 46. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 47. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2015-2020)
Table 48. Europe Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (2019-2020) (Million US$)
Table 49. Europe Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share (2019-2020)
Table 50. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 51. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2015-2020)
Table 52. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 53. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2015-2020)
Table 54. China Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (2019-2020) (Million US$)
Table 55. China Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share (2019-2020)
Table 56. China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 57. China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2015-2020)
Table 58. China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 59. China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2015-2020)
Table 60. Japan Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (2019-2020) (Million US$)
Table 61. Japan Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share (2019-2020)
Table 62. Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 63. Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2015-2020)
Table 64. Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 65. Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2015-2020)
Table 66. Southeast Asia Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (2019-2020) (Million US$)
Table 67. Southeast Asia Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share (2019-2020)
Table 68. Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 69. Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2015-2020)
Table 70. Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 71. Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2015-2020)
Table 72. India Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (2019-2020) (Million US$)
Table 73. India Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share (2019-2020)
Table 74. India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 75. India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2015-2020)
Table 76. India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 77. India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2015-2020)
Table 78. Central & South America Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (2019-2020) (Million US$)
Table 79. Central & South America Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share (2019-2020)
Table 80. Central & South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 81. Central & South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2015-2020)
Table 82. Central & South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 83. Central & South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2015-2020)
Table 84. Beta Pharma Company Details
Table 85. Beta Pharma Business Overview
Table 86. Beta Pharma Product
Table 87. Beta Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 88. Beta Pharma Recent Development
Table 89. AstraZeneca Company Details
Table 90. AstraZeneca Business Overview
Table 91. AstraZeneca Product
Table 92. AstraZeneca Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 93. AstraZeneca Recent Development
Table 94. Natco Pharma Company Details
Table 95. Natco Pharma Business Overview
Table 96. Natco Pharma Product
Table 97. Natco Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 98. Natco Pharma Recent Development
Table 99. Qilu Pharmaceutical Company Details
Table 100. Qilu Pharmaceutical Business Overview
Table 101. Qilu Pharmaceutical Product
Table 102. Qilu Pharmaceutical Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 103. Qilu Pharmaceutical Recent Development
Table 104. Genentech (Roche Group) Company Details
Table 105. Genentech (Roche Group) Business Overview
Table 106. Genentech (Roche Group) Product
Table 107. Genentech (Roche Group) Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 108. Genentech (Roche Group) Recent Development
Table 109. Mylan Company Details
Table 110. Mylan Business Overview
Table 111. Mylan Product
Table 112. Mylan Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 113. Mylan Recent Development
Table 114. Teva Company Details
Table 115. Teva Business Overview
Table 116. Teva Product
Table 117. Teva Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 118. Teva Recent Development
Table 119. OSI Pharmaceuticals Business Overview
Table 120. OSI Pharmaceuticals Product
Table 121. OSI Pharmaceuticals Company Details
Table 122. OSI Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 123. OSI Pharmaceuticals Recent Development
Table 124. Glenmark Pharmaceuticals Company Details
Table 125. Glenmark Pharmaceuticals Business Overview
Table 126. Glenmark Pharmaceuticals Product
Table 127. Glenmark Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 128. Glenmark Pharmaceuticals Recent Development
Table 129. Beacon Pharmaceuticals Company Details
Table 130. Beacon Pharmaceuticals Business Overview
Table 131. Beacon Pharmaceuticals Product
Table 132. Beacon Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 133. Beacon Pharmaceuticals Recent Development
Table 134. Boehringer Ingelheim Company Details
Table 135. Boehringer Ingelheim Business Overview
Table 136. Boehringer Ingelheim Product
Table 137. Boehringer Ingelheim Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 138. Boehringer Ingelheim Recent Development
Table 139. Pfizer Company Details
Table 140. Pfizer Business Overview
Table 141. Pfizer Product
Table 142. Pfizer Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 143. Pfizer Recent Development
Table 144. ARIAD Pharmaceuticals (Takeda) Company Details
Table 145. ARIAD Pharmaceuticals (Takeda) Business Overview
Table 146. ARIAD Pharmaceuticals (Takeda) Product
Table 147. ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 148. ARIAD Pharmaceuticals (Takeda) Recent Development
Table 149. Genvio Pharma Limited Company Details
Table 150. Genvio Pharma Limited Business Overview
Table 151. Genvio Pharma Limited Product
Table 152. Genvio Pharma Limited Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 153. Genvio Pharma Limited Recent Development
Table 154. Drug International Limted Company Details
Table 155. Drug International Limted Business Overview
Table 156. Drug International Limted Product
Table 157. Drug International Limted Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 158. Drug International Limted Recent Development
Table 159. Everest Pharmaceuticals Company Details
Table 160. Everest Pharmaceuticals Business Overview
Table 161. Everest Pharmaceuticals Product
Table 162. Everest Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 163. Everest Pharmaceuticals Recent Development
Table 164. Incepta Pharmaceuticals Limited Company Details
Table 165. Incepta Pharmaceuticals Limited Business Overview
Table 166. Incepta Pharmaceuticals Limited Product
Table 167. Incepta Pharmaceuticals Limited Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 168. Incepta Pharmaceuticals Limited Recent Development
Table 169. Cipla Pharma Company Details
Table 170. Cipla Pharma Business Overview
Table 171. Cipla Pharma Product
Table 172. Cipla Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 173. Cipla Pharma Recent Development
Table 174. Dr Reddy's Laboratories Company Details
Table 175. Dr Reddy's Laboratories Business Overview
Table 176. Dr Reddy's Laboratories Product
Table 177. Dr Reddy's Laboratories Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 178. Dr Reddy's Laboratories Recent Development
Table 179. Zydus Cadila Company Details
Table 180. Zydus Cadila Business Overview
Table 181. Zydus Cadila Product
Table 182. Zydus Cadila Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 183. Zydus Cadila Recent Development
Table 184. Hetero Drugs Company Details
Table 185. Hetero Drugs Business Overview
Table 186. Hetero Drugs Product
Table 187. Hetero Drugs Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 188. Hetero Drugs Recent Development
Table 189. Intas Pharmaceuticals Company Details
Table 190. Intas Pharmaceuticals Business Overview
Table 191. Intas Pharmaceuticals Product
Table 192. Intas Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 193. Intas Pharmaceuticals Recent Development
Table 194. Alkem Laboratories Company Details
Table 195. Alkem Laboratories Business Overview
Table 196. Alkem Laboratories Product
Table 197. Alkem Laboratories Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 198. Alkem Laboratories Recent Development
Table 199. RPG Life Sciences Company Details
Table 200. RPG Life Sciences Business Overview
Table 201. RPG Life Sciences Product
Table 202. RPG Life Sciences Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 203. RPG Life Sciences Recent Development
Table 204. Fresenius Kabi India Company Details
Table 205. Fresenius Kabi India Business Overview
Table 206. Fresenius Kabi India Product
Table 207. Fresenius Kabi India Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 208. Fresenius Kabi India Recent Development
Table 209. Research Programs/Design for This Report
Table 210. Key Data Information from Secondary Sources
Table 211. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type: 2020 VS 2026
Figure 2. Icotinib Features
Figure 3. Gefitinib Features
Figure 4. Erlotinib Features
Figure 5. Afatinib Features
Figure 6. Osimertinib Features
Figure 7. Brigatinib Features
Figure 8. Other Features
Figure 9. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application: 2020 VS 2026
Figure 10. Squamous Cell Carcinoma of NSCLC Case Studies
Figure 11. Adenocarcinoma of NSCLC Case Studies
Figure 12. Large Cell Carcinoma of NSCLC Case Studies
Figure 13. Targeted Drug EGFR RTK Inhibitors for NSCLC Report Years Considered
Figure 14. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth 2015-2026 (US$ Million)
Figure 15. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Regions: 2020 VS 2026
Figure 16. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Regions (2021-2026)
Figure 17. Porter's Five Forces Analysis
Figure 18. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Players in 2019
Figure 19. Global Top Targeted Drug EGFR RTK Inhibitors for NSCLC Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC as of 2019
Figure 20. The Top 10 and 5 Players Market Share by Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue in 2019
Figure 21. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Central & South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Beta Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. Beta Pharma Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 30. AstraZeneca Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. AstraZeneca Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 32. Natco Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Natco Pharma Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 34. Qilu Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. Qilu Pharmaceutical Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 36. Genentech (Roche Group) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. Genentech (Roche Group) Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 38. Mylan Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. Mylan Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 40. Teva Total Revenue (US$ Million): 2019 Compared with 2018
Figure 41. Teva Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 42. OSI Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 43. OSI Pharmaceuticals Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 44. Glenmark Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 45. Glenmark Pharmaceuticals Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 46. Beacon Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 47. Beacon Pharmaceuticals Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 48. Boehringer Ingelheim Total Revenue (US$ Million): 2019 Compared with 2018
Figure 49. Boehringer Ingelheim Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 50. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. Pfizer Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 52. ARIAD Pharmaceuticals (Takeda) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. ARIAD Pharmaceuticals (Takeda) Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 54. Genvio Pharma Limited Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Genvio Pharma Limited Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 56. Drug International Limted Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. Drug International Limted Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 58. Everest Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. Everest Pharmaceuticals Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 60. Incepta Pharmaceuticals Limited Total Revenue (US$ Million): 2019 Compared with 2018
Figure 61. Incepta Pharmaceuticals Limited Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 62. Cipla Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 63. Cipla Pharma Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 64. Dr Reddy's Laboratories Total Revenue (US$ Million): 2019 Compared with 2018
Figure 65. Dr Reddy's Laboratories Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 66. Zydus Cadila Total Revenue (US$ Million): 2019 Compared with 2018
Figure 67. Zydus Cadila Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
Figure 1. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type: 2020 VS 2026
Figure 2. Icotinib Features
Figure 3. Gefitinib Features
Figure 4. Erlotinib Features
Figure 5. Afatinib Features
Figure 6. Osimertinib Features
Figure 7. Brigatinib Features
Figure 8. Other Features
Figure 9. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application: 2020 VS 2026
Figure 10. Squamous Cell Carcinoma of NSCLC Case Studies
Figure 11. Adenocarcinoma of NSCLC Case Studies
Figure 12. Large Cell Carcinoma of NSCLC Case Studies
Figure 13. Targeted Drug EGFR RTK Inhibitors for NSCLC Report Years Considered
Figure 14. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth 2015-2026 (US$ Million)
Figure 15. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Regions: 2020 VS 2026
Figure 16. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Regions (2021-2026)
Figure 17. Porter's Five Forces Analysis
Figure 18. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Players in 2019
Figure 19. Global Top Targeted Drug EGFR RTK Inhibitors for NSCLC Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC as of 2019
Figure 20. The Top 10 and 5 Players Market Share by Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue in 2019
Figure 21. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Central & South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Beta Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. Beta Pharma Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 30. AstraZeneca Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. AstraZeneca Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 32. Natco Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Natco Pharma Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 34. Qilu Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. Qilu Pharmaceutical Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 36. Genentech (Roche Group) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. Genentech (Roche Group) Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 38. Mylan Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. Mylan Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 40. Teva Total Revenue (US$ Million): 2019 Compared with 2018
Figure 41. Teva Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 42. OSI Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 43. OSI Pharmaceuticals Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 44. Glenmark Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 45. Glenmark Pharmaceuticals Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 46. Beacon Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 47. Beacon Pharmaceuticals Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 48. Boehringer Ingelheim Total Revenue (US$ Million): 2019 Compared with 2018
Figure 49. Boehringer Ingelheim Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 50. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. Pfizer Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 52. ARIAD Pharmaceuticals (Takeda) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. ARIAD Pharmaceuticals (Takeda) Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 54. Genvio Pharma Limited Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Genvio Pharma Limited Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 56. Drug International Limted Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. Drug International Limted Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 58. Everest Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. Everest Pharmaceuticals Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 60. Incepta Pharmaceuticals Limited Total Revenue (US$ Million): 2019 Compared with 2018
Figure 61. Incepta Pharmaceuticals Limited Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 62. Cipla Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 63. Cipla Pharma Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 64. Dr Reddy's Laboratories Total Revenue (US$ Million): 2019 Compared with 2018
Figure 65. Dr Reddy's Laboratories Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 66. Zydus Cadila Total Revenue (US$ Million): 2019 Compared with 2018
Figure 67. Zydus Cadila Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2015-2020)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
